{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T05:16:55Z","timestamp":1731993415651,"version":"3.28.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,17]]},"DOI":"10.7759\/cureus.73882","type":"journal-article","created":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T07:17:15Z","timestamp":1731914235000},"source":"Crossref","is-referenced-by-count":0,"title":["The Management of Osteoporosis in Chronic Kidney Disease: A Review of Diagnostic and Therapeutic Approaches"],"prefix":"10.7759","author":[{"given":"Fatima","family":"Tariq","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehjabeen","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Subhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syed Muhammad","family":"Zaid Alvi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Umar","family":"Tariq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sami","family":"Ullah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asma","family":"Khalid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruqiya","family":"Bibi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muaz","family":"Shafique Ur Rehman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayesha","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s11914-018-0491-3","article-title":"Updates in CKD-associated osteoporosis","volume":"16","author":"Khairallah P","year":"2018","unstructured":"Khairallah P, Nickolas TL. Updates in CKD-associated osteoporosis. Curr Osteoporos Rep. 2018, 16:712-23. 10.1007\/s11914-018-0491-3","journal-title":"Curr Osteoporos Rep"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-022-06462-3","article-title":"Management of osteoporosis in patients with chronic kidney disease","volume":"33","author":"Abdalbary M","year":"2022","unstructured":"Abdalbary M, Sobh M, Elnagar S, et al.. Management of osteoporosis in patients with chronic kidney disease. Osteoporos Int. 2022, 33:2259-74. 10.1007\/s00198-022-06462-3","journal-title":"Osteoporos Int"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2021.06.031","article-title":"Diagnosis and management of osteoporosis in advanced kidney disease: a review","volume":"79","author":"Ginsberg C","year":"2022","unstructured":"Ginsberg C, Ix JH. Diagnosis and management of osteoporosis in advanced kidney disease: a review. Am J Kidney Dis. 2022, 79:427-36. 10.1053\/j.ajkd.2021.06.031","journal-title":"Am J Kidney Dis"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2020.12.024","article-title":"Osteoporosis and chronic kidney disease-mineral and bone disorder (CKD-MBD): back to basics","volume":"78","author":"Pazianas M","year":"2021","unstructured":"Pazianas M, Miller PD. Osteoporosis and chronic kidney disease-mineral and bone disorder (CKD-MBD): back to basics. Am J Kidney Dis. 2021, 78:582-9. 10.1053\/j.ajkd.2020.12.024","journal-title":"Am J Kidney Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21186846","article-title":"Osteoporosis in patients with chronic kidney diseases: a systemic review","volume":"21","author":"Hsu CY","year":"2020","unstructured":"Hsu CY, Chen LR, Chen KH. Osteoporosis in patients with chronic kidney diseases: a systemic review. Int J Mol Sci. 2020, 21:6846. 10.3390\/ijms21186846","journal-title":"Int J Mol Sci"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-018-4688-1","article-title":"Impaired residual renal function predicts denosumab-induced serum calcium decrement as well as increment of bone mineral density in non-severe renal insufficiency","volume":"30","author":"Miyaoka D","year":"2019","unstructured":"Miyaoka D, Imanishi Y, Ohara M, et al.. Impaired residual renal function predicts denosumab-induced serum calcium decrement as well as increment of bone mineral density in non-severe renal insufficiency. Osteoporos Int. 2019, 30:241-9. 10.1007\/s00198-018-4688-1","journal-title":"Osteoporos Int"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-020-00786-0","article-title":"Traditional and non-traditional risk factors for osteoporosis in CKD","volume":"108","author":"J\u00f8rgensen HS","year":"2021","unstructured":"J\u00f8rgensen HS, David K, Salam S, Evenepoel P. Traditional and non-traditional risk factors for osteoporosis in CKD. Calcif Tissue Int. 2021, 108:496-511. 10.1007\/s00223-020-00786-0","journal-title":"Calcif Tissue Int"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232012223","article-title":"Mineral bone disorders in kidney disease patients: the ever-current topic","volume":"23","author":"Hu L","year":"2022","unstructured":"Hu L, Napoletano A, Provenzano M, Garofalo C, Bini C, Comai G, La Manna G. Mineral bone disorders in kidney disease patients: the ever-current topic. Int J Mol Sci. 2022, 23:12223. 10.3390\/ijms232012223","journal-title":"Int J Mol Sci"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaa192","article-title":"European consensus statement on the diagnosis and management of osteoporosis in chronic kidney disease stages G4-G5D","volume":"36","author":"Evenepoel P","year":"2021","unstructured":"Evenepoel P, Cunningham J, Ferrari S, et al.. European consensus statement on the diagnosis and management of osteoporosis in chronic kidney disease stages G4-G5D. Nephrol Dial Transplant. 2021, 36:42-59. 10.1093\/ndt\/gfaa192","journal-title":"Nephrol Dial Transplant"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2023.1177829","article-title":"Pathophysiology of bone disease in chronic kidney disease: from basics to renal osteodystrophy and osteoporosis","volume":"14","author":"Aguilar A","year":"2023","unstructured":"Aguilar A, Gifre L, Ure\u00f1a-Torres P, et al.. Pathophysiology of bone disease in chronic kidney disease: from basics to renal osteodystrophy and osteoporosis. Front Physiol. 2023, 14:1177829. 10.3389\/fphys.2023.1177829","journal-title":"Front Physiol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/nu15041007","article-title":"An evaluation of the implementation of the European Calcified Tissue Society recommendations on the prevention and treatment of osteoporosis secondary to bariatric surgery","volume":"15","author":"Courtalin M","year":"2023","unstructured":"Courtalin M, Verkindt H, Oukhouya Daoud N, Ramdane N, Cortet B, Pattou F, Paccou J. An evaluation of the implementation of the European Calcified Tissue Society recommendations on the prevention and treatment of osteoporosis secondary to bariatric surgery. Nutrients. 2023, 15:1007. 10.3390\/nu15041007","journal-title":"Nutrients"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s43465-023-01021-2","article-title":"Osteoporosis in renal disease","volume":"57","author":"Tiwari JP","year":"2023","unstructured":"Tiwari JP. Osteoporosis in renal disease. Indian J Orthop. 2023, 57:192-9. 10.1007\/s43465-023-01021-2","journal-title":"Indian J Orthop"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/nu15010167","article-title":"Bone disease in chronic kidney disease and kidney transplant","volume":"15","author":"Bellorin-Font E","year":"2022","unstructured":"Bellorin-Font E, Rojas E, Martin KJ. Bone disease in chronic kidney disease and kidney transplant. Nutrients. 2022, 15:167. 10.3390\/nu15010167","journal-title":"Nutrients"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/nu13041372","article-title":"Diet, nutrition and chronic degenerative diseases","volume":"13","author":"Di Renzo L","year":"2021","unstructured":"Di Renzo L, Gualtieri P, De Lorenzo A. Diet, nutrition and chronic degenerative diseases. Nutrients. 2021, 13:1372. 10.3390\/nu13041372","journal-title":"Nutrients"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s11657-021-00971-0","article-title":"Denosumab in chronic kidney disease: a narrative review of treatment efficacy and safety","volume":"16","author":"Gopaul A","year":"2021","unstructured":"Gopaul A, Kanagalingam T, Thain J, Khan T, Cowan A, Sultan N, Clemens KK. Denosumab in chronic kidney disease: a narrative review of treatment efficacy and safety. Arch Osteoporos. 2021, 16:116. 10.1007\/s11657-021-00971-0","journal-title":"Arch Osteoporos"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.822178","article-title":"Efficacy of osteoporosis medications for patients with chronic kidney disease: an updated systematic review and network meta-analysis","volume":"13","author":"Chen CH","year":"2022","unstructured":"Chen CH, Lo WC, Hu PJ, Chan HC, Shen WC, Wu MS, Wu MY. Efficacy of osteoporosis medications for patients with chronic kidney disease: an updated systematic review and network meta-analysis. Front Pharmacol. 2022, 13:822178. 10.3389\/fphar.2022.822178","journal-title":"Front Pharmacol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-017-0478-9","article-title":"Risedronate therapy in patients with mild-to-moderate chronic kidney disease with osteoporosis: post-hoc analysis of data from the risedronate phase III clinical trials","volume":"18","author":"Shigematsu T","year":"2017","unstructured":"Shigematsu T, Muraoka R, Sugimoto T, Nishizawa Y. Risedronate therapy in patients with mild-to-moderate chronic kidney disease with osteoporosis: post-hoc analysis of data from the risedronate phase III clinical trials. BMC Nephrol. 2017, 18:66. 10.1186\/s12882-017-0478-9","journal-title":"BMC Nephrol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-020-00777-1","article-title":"Chronic kidney disease-mineral and bone disorders: pathogenesis and management","volume":"108","author":"Cannata-And\u00eda JB","year":"2021","unstructured":"Cannata-And\u00eda JB, Mart\u00edn-Carro B, Mart\u00edn-V\u00edrgala J, Rodr\u00edguez-Carrio J, Bande-Fern\u00e1ndez JJ, Alonso-Montes C, Carrillo-L\u00f3pez N. Chronic kidney disease-mineral and bone disorders: pathogenesis and management. Calcif Tissue Int. 2021, 108:410-22. 10.1007\/s00223-020-00777-1","journal-title":"Calcif Tissue Int"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-022-01031-6","article-title":"One-year romosozumab treatment followed by one-year denosumab treatment for osteoporosis in patients on hemodialysis: an observational study","volume":"112","author":"Saito T","year":"2023","unstructured":"Saito T, Mizobuchi M, Kato T, et al.. One-year romosozumab treatment followed by one-year denosumab treatment for osteoporosis in patients on hemodialysis: an observational study. Calcif Tissue Int. 2023, 112:34-44. 10.1007\/s00223-022-01031-6","journal-title":"Calcif Tissue Int"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.4563","article-title":"Efficacy and safety of romosozumab among postmenopausal women with osteoporosis and mild-to-moderate chronic kidney disease","volume":"37","author":"Miller PD","year":"2022","unstructured":"Miller PD, Adachi JD, Albergaria BH, et al.. Efficacy and safety of romosozumab among postmenopausal women with osteoporosis and mild-to-moderate chronic kidney disease. J Bone Miner Res. 2022, 37:1437-45. 10.1002\/jbmr.4563","journal-title":"J Bone Miner Res"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-020-00779-z","article-title":"Bone fragility fractures in CKD patients","volume":"108","author":"Pimentel A","year":"2021","unstructured":"Pimentel A, Ure\u00f1a-Torres P, Bover J, Luis Fernandez-Mart\u00edn J, Cohen-Solal M. Bone fragility fractures in CKD patients. Calcif Tissue Int. 2021, 108:539-50. 10.1007\/s00223-020-00779-z","journal-title":"Calcif Tissue Int"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-021-00856-x","article-title":"The role of bone biopsy in the management of CKD-MBD and osteoporosis","volume":"109","author":"Pazianas M","year":"2021","unstructured":"Pazianas M. The role of bone biopsy in the management of CKD-MBD and osteoporosis. Calcif Tissue Int. 2021, 109:110-1. 10.1007\/s00223-021-00856-x","journal-title":"Calcif Tissue Int"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3821","article-title":"Denosumab improves glomerular filtration rate in osteoporotic patients with normal kidney function by lowering serum phosphorus","volume":"34","author":"Miyaoka D","year":"2019","unstructured":"Miyaoka D, Inaba M, Imanishi Y, et al.. Denosumab improves glomerular filtration rate in osteoporotic patients with normal kidney function by lowering serum phosphorus. J Bone Miner Res. 2019, 34:2028-35. 10.1002\/jbmr.3821","journal-title":"J Bone Miner Res"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.2147\/RMHP.S426869","article-title":"Denosumab use in chronic kidney disease associated osteoporosis: a narrative review","volume":"16","author":"Abduelkarem AR","year":"2023","unstructured":"Abduelkarem AR, Guella A, Hamrouni AM, Hassanein MM, Nasr A, Rana O. Denosumab use in chronic kidney disease associated osteoporosis: a narrative review. Risk Manag Healthc Policy. 2023, 16:1809-13. 10.2147\/RMHP.S426869","journal-title":"Risk Manag Healthc Policy"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone HG","year":"2017","unstructured":"Bone HG, Wagman RB, Brandi ML, et al.. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017, 5:513-23. 10.1016\/S2213-8587(17)30138-9","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-023-03381-z","article-title":"Denosumab for osteoporosis in patients with primary hyperparathyroidism and mild-to-moderate renal insufficiency","volume":"81","author":"Gronskaya S","year":"2023","unstructured":"Gronskaya S, Belaya Z, Rozhinskaya L, et al.. Denosumab for osteoporosis in patients with primary hyperparathyroidism and mild-to-moderate renal insufficiency. Endocrine. 2023, 81:368-78. 10.1007\/s12020-023-03381-z","journal-title":"Endocrine"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2015.315","article-title":"Raloxifene improves skeletal properties in an animal model of cystic chronic kidney disease","volume":"89","author":"Newman CL","year":"2016","unstructured":"Newman CL, Creecy A, Granke M, et al.. Raloxifene improves skeletal properties in an animal model of cystic chronic kidney disease. Kidney Int. 2016, 89:95-104. 10.1038\/ki.2015.315","journal-title":"Kidney Int"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.1032219","article-title":"Editorial: management of osteoporosis in patients with chronic kidney disease","volume":"9","author":"Abdalbary M","year":"2022","unstructured":"Abdalbary M, Sobh M, Nagy E, et al.. Editorial: management of osteoporosis in patients with chronic kidney disease. Front Med (Lausanne). 2022, 9:1032219. 10.3389\/fmed.2022.1032219","journal-title":"Front Med (Lausanne)"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1177\/10815589231184215","article-title":"Efficacy and safety of medications for osteoporosis in kidney transplant recipients or patients with chronic kidney disease: a meta-analysis","volume":"71","author":"Leng Y","year":"2023","unstructured":"Leng Y, Yu X, Yang Y, Xia Y. Efficacy and safety of medications for osteoporosis in kidney transplant recipients or patients with chronic kidney disease: a meta-analysis. J Investig Med. 2023, 71:760-72. 10.1177\/10815589231184215","journal-title":"J Investig Med"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.nefro.2017.12.006","article-title":"Osteoporosis, bone mineral density and CKD-MBD complex (I): diagnostic considerations","volume":"38","author":"Bover J","year":"2018","unstructured":"Bover J, Ure\u00f1a-Torres P, Torregrosa JV, et al.. Osteoporosis, bone mineral density and CKD-MBD complex (I): diagnostic considerations. Nefrologia (Engl Ed). 2018, 38:476-90. 10.1016\/j.nefro.2017.12.006","journal-title":"Nefrologia (Engl Ed)"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2021.07.005","article-title":"Prescription patterns of osteoporosis medications in patients with advanced CKD: a retrospective cohort study","volume":"3","author":"Portales-Castillo IA","year":"2021","unstructured":"Portales-Castillo IA, Aksu C, Zhao S, Strohbehn I, Sise M, Yu EW, Nigwekar SU. Prescription patterns of osteoporosis medications in patients with advanced CKD: a retrospective cohort study. Kidney Med. 2021, 3:1112-5. 10.1016\/j.xkme.2021.07.005","journal-title":"Kidney Med"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1055\/a-1655-4362","article-title":"Raloxifene in the treatment of osteoporosis in postmenopausal women with end-stage renal disease: a systematic review and meta-analysis","volume":"53","author":"Ma HY","year":"2021","unstructured":"Ma HY, Chen S, Lu LL, Gong W, Zhang AH. Raloxifene in the treatment of osteoporosis in postmenopausal women with end-stage renal disease: a systematic review and meta-analysis. Horm Metab Res. 2021, 53:730-7. 10.1055\/a-1655-4362","journal-title":"Horm Metab Res"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-021-00854-z","article-title":"The role of bone biopsy in the management of CKD-MBD: CKD-related osteoporosis or CKD-MBD\/osteoporosis?","volume":"109","author":"Ferreira AC","year":"2021","unstructured":"Ferreira AC, Cohen-Solal M, D'Haese PC, Ferreira A. The role of bone biopsy in the management of CKD-MBD: CKD-related osteoporosis or CKD-MBD\/osteoporosis?. Calcif Tissue Int. 2021, 109:112. 10.1007\/s00223-021-00854-z","journal-title":"Calcif Tissue Int"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.afos.2023.11.002","article-title":"Teriparatide and etelcalcetide improve bone, fibrosis, and fat parameters in chronic kidney disease model rats","volume":"9","author":"Igarashi S","year":"2023","unstructured":"Igarashi S, Kasukawa Y, Nozaka K, et al.. Teriparatide and etelcalcetide improve bone, fibrosis, and fat parameters in chronic kidney disease model rats. Osteoporos Sarcopenia. 2023, 9:121-30. 10.1016\/j.afos.2023.11.002","journal-title":"Osteoporos Sarcopenia"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.nefro.2018.10.009","article-title":"Osteoporosis, bone mineral density and CKD-MBD (II): therapeutic implications","volume":"39","author":"Bover J","year":"2019","unstructured":"Bover J, Ure\u00f1a-Torres P, Laiz Alonso AM, et al.. Osteoporosis, bone mineral density and CKD-MBD (II): therapeutic implications. Nefrologia (Engl Ed). 2019, 39:227-42. 10.1016\/j.nefro.2018.10.009","journal-title":"Nefrologia (Engl Ed)"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.25259\/ijn_555_23","article-title":"Teriparatide improves bone formation markers and bone mineral density in adynamic bone disease associated with chronic kidney disease","volume":"34","author":"Jha VK","year":"2024","unstructured":"Jha VK, Abhisheka K, Akal RS, Mahapatra D, Rai SK. Teriparatide improves bone formation markers and bone mineral density in adynamic bone disease associated with chronic kidney disease. Indian J Nephrol. 2024, 34:254-6. 10.25259\/ijn_555_23","journal-title":"Indian J Nephrol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-016-3858-2","article-title":"Teriparatide treatment in a heart transplant patient with a chronic kidney disease and a low-turnover bone disease: a case report","volume":"28","author":"Fahrleitner-Pammer A","year":"2017","unstructured":"Fahrleitner-Pammer A, Wagner D, Krisper P, Amrein K, Dimai H. Teriparatide treatment in a heart transplant patient with a chronic kidney disease and a low-turnover bone disease: a case report. Osteoporos Int. 2017, 28:1149-52. 10.1007\/s00198-016-3858-2","journal-title":"Osteoporos Int"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1097\/MNH.0000000000000411","article-title":"Fracture risk and treatment in chronic kidney disease","volume":"27","author":"Connelly K","year":"2018","unstructured":"Connelly K, Collister D, Tangri N. Fracture risk and treatment in chronic kidney disease. Curr Opin Nephrol Hypertens. 2018, 27:221-5. 10.1097\/MNH.0000000000000411","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.607017","article-title":"Combination therapy of PTH and antiresorptive drugs on osteoporosis: a review of treatment alternatives","volume":"11","author":"Zhang C","year":"2020","unstructured":"Zhang C, Song C. Combination therapy of PTH and antiresorptive drugs on osteoporosis: a review of treatment alternatives. Front Pharmacol. 2020, 11:607017. 10.3389\/fphar.2020.607017","journal-title":"Front Pharmacol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1136\/postgradmedj-2021-140341","article-title":"Effects of osteoporosis medications on bone fracture in patients with chronic kidney disease","volume":"99","author":"Kao CC","year":"2023","unstructured":"Kao CC, Wu PC, Chuang MT, et al.. Effects of osteoporosis medications on bone fracture in patients with chronic kidney disease. Postgrad Med J. 2023, 99:340-9. 10.1136\/postgradmedj-2021-140341","journal-title":"Postgrad Med J"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1007\/s11657-022-01179-6","article-title":"Challenges in osteoporosis treatment initiation in geriatric patients admitted under the hip-fracture pathway","volume":"17","author":"Wen AF","year":"2022","unstructured":"Wen AF, Chong BY, Joseph LV, Bee JK, Sen HT, Mamun K. Challenges in osteoporosis treatment initiation in geriatric patients admitted under the hip-fracture pathway. Arch Osteoporos. 2022, 17:136. 10.1007\/s11657-022-01179-6","journal-title":"Arch Osteoporos"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.nefroe.2024.03.005","article-title":"Osteoporosis management in patients with chronic kidney disease (ERCOS Study): a challenge in nephrological care","volume":"44","author":"Bover J","year":"2024","unstructured":"Bover J, G\u00f3mez-Alonso C, Casado E, et al.. Osteoporosis management in patients with chronic kidney disease (ERCOS Study): a challenge in nephrological care. Nefrologia (Engl Ed). 2024, 44:241-50. 10.1016\/j.nefroe.2024.03.005","journal-title":"Nefrologia (Engl Ed)"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-020-00781-5","article-title":"The non-invasive diagnosis of bone disorders in CKD","volume":"108","author":"Bover J","year":"2021","unstructured":"Bover J, Ure\u00f1a-Torres P, Cozzolino M, Rodr\u00edguez-Garc\u00eda M, G\u00f3mez-Alonso C. The non-invasive diagnosis of bone disorders in CKD. Calcif Tissue Int. 2021, 108:512-27. 10.1007\/s00223-020-00781-5","journal-title":"Calcif Tissue Int"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-015-3377-6","article-title":"Once-weekly teriparatide in hemodialysis patients with hypoparathyroidism and low bone mass: a prospective study","volume":"27","author":"Sumida K","year":"2016","unstructured":"Sumida K, Ubara Y, Hoshino J, et al.. Once-weekly teriparatide in hemodialysis patients with hypoparathyroidism and low bone mass: a prospective study. Osteoporos Int. 2016, 27:1441-50. 10.1007\/s00198-015-3377-6","journal-title":"Osteoporos Int"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.2147\/CIA.S120175","article-title":"Safety and effectiveness of daily teriparatide for osteoporosis in patients with severe stages of chronic kidney disease: post hoc analysis of a postmarketing observational study","volume":"11","author":"Nishikawa A","year":"2016","unstructured":"Nishikawa A, Yoshiki F, Taketsuna M, Kajimoto K, Enomoto H. Safety and effectiveness of daily teriparatide for osteoporosis in patients with severe stages of chronic kidney disease: post hoc analysis of a postmarketing observational study. Clin Interv Aging. 2016, 11:1653-9. 10.2147\/CIA.S120175","journal-title":"Clin Interv Aging"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10071403","article-title":"Review of current real-world experience with teriparatide as treatment of osteoporosis in different patient groups","volume":"10","author":"Hauser B","year":"2021","unstructured":"Hauser B, Alonso N, Riches PL. Review of current real-world experience with teriparatide as treatment of osteoporosis in different patient groups. J Clin Med. 2021, 10:1403. 10.3390\/jcm10071403","journal-title":"J Clin Med"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1210\/en.2015-1726","article-title":"Binding selectivity of abaloparatide for PTH-type-1-receptor conformations and effects on downstream signaling","volume":"157","author":"Hattersley G","year":"2016","unstructured":"Hattersley G, Dean T, Corbin BA, Bahar H, Gardella TJ. Binding selectivity of abaloparatide for PTH-type-1-receptor conformations and effects on downstream signaling. Endocrinology. 2016, 157:141-9. 10.1210\/en.2015-1726","journal-title":"Endocrinology"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1007\/s11657-019-0564-7","article-title":"Effect of abaloparatide on vertebral, nonvertebral, major osteoporotic, and clinical fractures in a subset of postmenopausal women at increased risk of fracture by FRAX probability","volume":"14","author":"McCloskey EV","year":"2019","unstructured":"McCloskey EV, Fitzpatrick LA, Hu MY, Williams G, Kanis JA. Effect of abaloparatide on vertebral, nonvertebral, major osteoporotic, and clinical fractures in a subset of postmenopausal women at increased risk of fracture by FRAX probability. Arch Osteoporos. 2019, 14:15. 10.1007\/s11657-019-0564-7","journal-title":"Arch Osteoporos"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.11136","article-title":"Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial","volume":"316","author":"Miller PD","year":"2016","unstructured":"Miller PD, Hattersley G, Riis BJ, et al.. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA. 2016, 316:722-33. 10.1001\/jama.2016.11136","journal-title":"JAMA"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2016.11.004","article-title":"Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: the ACTIVE phase 3 trial","volume":"97","author":"Moreira CA","year":"2017","unstructured":"Moreira CA, Fitzpatrick LA, Wang Y, Recker RR. Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: the ACTIVE phase 3 trial. Bone. 2017, 97:314-9. 10.1016\/j.bone.2016.11.004","journal-title":"Bone"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.11031017","article-title":"Management of osteoporosis in CKD","volume":"13","author":"Khairallah P","year":"2018","unstructured":"Khairallah P, Nickolas TL. Management of osteoporosis in CKD. Clin J Am Soc Nephrol. 2018, 13:962-9. 10.2215\/CJN.11031017","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2022.05.020","article-title":"Effectiveness of pharmacological interventions versus placebo or no treatment for osteoporosis in patients with CKD Stages 3-5d: editorial summary of a Cochrane review","volume":"80","author":"Hara T","year":"2022","unstructured":"Hara T, Hijikata Y, Matsubara Y. Effectiveness of pharmacological interventions versus placebo or no treatment for osteoporosis in patients with CKD Stages 3-5d: editorial summary of a Cochrane review. Am J Kidney Dis. 2022, 80:794-6. 10.1053\/j.ajkd.2022.05.020","journal-title":"Am J Kidney Dis"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfv005","article-title":"Treatment of adynamic bone disease in a haemodialysis patient with teriparatide","volume":"8","author":"Giamalis P","year":"2015","unstructured":"Giamalis P, Economidou D, Dimitriadis C, Memmos D, Papagianni A, Efstratiadis G. Treatment of adynamic bone disease in a haemodialysis patient with teriparatide. Clin Kidney J. 2015, 8:188-90. 10.1093\/ckj\/sfv005","journal-title":"Clin Kidney J"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1053\/j.ackd.2019.09.006","article-title":"Bone-vascular axis in chronic kidney disease","volume":"26","author":"Evenepoel P","year":"2019","unstructured":"Evenepoel P, Opdebeeck B, David K, D'Haese PC. Bone-vascular axis in chronic kidney disease. Adv Chronic Kidney Dis. 2019, 26:472-83. 10.1053\/j.ackd.2019.09.006","journal-title":"Adv Chronic Kidney Dis"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2021.05.007","article-title":"Osteoporosis in chronic kidney disease: a essential challenge","volume":"158","author":"Casado E","year":"2022","unstructured":"Casado E, Bover J, G\u00f3mez-Alonso C, Navarro-Gonz\u00e1lez JF. Osteoporosis in chronic kidney disease: a essential challenge. Med Clin (Barc). 2022, 158:27-34. 10.1016\/j.medcli.2021.05.007","journal-title":"Med Clin (Barc)"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-021-05975-7","article-title":"Diagnosis and management of osteoporosis in chronic kidney disease stages 4 to 5D: a call for a shift from nihilism to pragmatism","volume":"32","author":"Evenepoel P","year":"2021","unstructured":"Evenepoel P, Cunningham J, Ferrari S, et al.. Diagnosis and management of osteoporosis in chronic kidney disease stages 4 to 5D: a call for a shift from nihilism to pragmatism. Osteoporos Int. 2021, 32:2397-405. 10.1007\/s00198-021-05975-7","journal-title":"Osteoporos Int"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2022.08.002","article-title":"Effectiveness of pharmacological interventions for treatment of osteoporosis in patients with CKD 3-5d: no clear choices","volume":"80","author":"Khairallah P","year":"2022","unstructured":"Khairallah P, Nickolas TL. Effectiveness of pharmacological interventions for treatment of osteoporosis in patients with CKD 3-5d: no clear choices. Am J Kidney Dis. 2022, 80:797-800. 10.1053\/j.ajkd.2022.08.002","journal-title":"Am J Kidney Dis"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.12182\/20210360507","article-title":"[A cross-sectional study of osteoporosis and cardiovascular calcification in patients with chronic kidney disease at different CKD stages] (Article in Chinese)","volume":"52","author":"Cai ZY","year":"2021","unstructured":"Cai ZY, Hu XF, Chen LQ, Li ZR, Du XG. [A cross-sectional study of osteoporosis and cardiovascular calcification in patients with chronic kidney disease at different CKD stages] (Article in Chinese). Sichuan Da Xue Xue Bao Yi Xue Ban. 2021, 52:334-9. 10.12182\/20210360507","journal-title":"Sichuan Da Xue Xue Bao Yi Xue Ban"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1007\/s00774-022-01332-8","article-title":"Efficacy and safety of romosozumab among Japanese postmenopausal women with osteoporosis and mild-to-moderate chronic kidney disease","volume":"40","author":"Miyauchi A","year":"2022","unstructured":"Miyauchi A, Hamaya E, Nishi K, Tolman C, Shimauchi J. Efficacy and safety of romosozumab among Japanese postmenopausal women with osteoporosis and mild-to-moderate chronic kidney disease. J Bone Miner Metab. 2022, 40:677-87. 10.1007\/s00774-022-01332-8","journal-title":"J Bone Miner Metab"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfy129","article-title":"Sclerostin in chronic kidney disease-mineral bone disorder think first before you block it!","volume":"34","author":"Brandenburg VM","year":"2019","unstructured":"Brandenburg VM, Verhulst A, Babler A, D'Haese PC, Evenepoel P, Kaesler N. Sclerostin in chronic kidney disease-mineral bone disorder think first before you block it!. Nephrol Dial Transplant. 2019, 34:408-14. 10.1093\/ndt\/gfy129","journal-title":"Nephrol Dial Transplant"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1016\/j.bonr.2022.101639","article-title":"Romosozumab improves low bone mineral density in a postmenopausal woman undergoing chronic hemodialysis and treated with a calcium-sensing receptor agonist","volume":"17","author":"Ogata M","year":"2022","unstructured":"Ogata M, Ushimaru S, Fujishima R, Sumi H, Shiizaki K, Tominaga N. Romosozumab improves low bone mineral density in a postmenopausal woman undergoing chronic hemodialysis and treated with a calcium-sensing receptor agonist. Bone Rep. 2022, 17:101639. 10.1016\/j.bonr.2022.101639","journal-title":"Bone Rep"},{"key":"ref62","article-title":"[Osteoporosis and chronic kidney disease: review and new therapeutic strategies] (Article in Italian)","volume":"36","author":"Sessa C","year":"2019","unstructured":"Sessa C, Galeano D, Alessandrello I, et al.. [Osteoporosis and chronic kidney disease: review and new therapeutic strategies] (Article in Italian). G Ital Nefrol. 2019, 36:","journal-title":"G Ital Nefrol"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1093\/jbmrpl\/ziae016","article-title":"Romosozumab added to ongoing denosumab in postmenopausal osteoporosis, a prospective observational study","volume":"8","author":"Adami G","year":"2024","unstructured":"Adami G, Pedrollo E, Rossini M, et al.. Romosozumab added to ongoing denosumab in postmenopausal osteoporosis, a prospective observational study. JBMR Plus. 2024, 8:ziae016. 10.1093\/jbmrpl\/ziae016","journal-title":"JBMR Plus"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30346-8","article-title":"Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study","volume":"7","author":"McClung MR","year":"2019","unstructured":"McClung MR, O'Donoghue ML, Papapoulos SE, et al.. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study. Lancet Diabetes Endocrinol. 2019, 7:899-911. 10.1016\/S2213-8587(19)30346-8","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1080\/0886022X.2024.2361802","article-title":"Risk factors and clinical prediction models for osteoporosis in pre-dialysis chronic kidney disease patients","volume":"46","author":"Kuang C","year":"2024","unstructured":"Kuang C, Shang J, Ma M, et al.. Risk factors and clinical prediction models for osteoporosis in pre-dialysis chronic kidney disease patients. Ren Fail. 2024, 46:2361802. 10.1080\/0886022X.2024.2361802","journal-title":"Ren Fail"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2020040411","article-title":"A randomized trial on the effect of phosphate reduction on vascular end points in CKD (IMPROVE-CKD)","volume":"31","author":"Toussaint ND","year":"2020","unstructured":"Toussaint ND, Pedagogos E, Lioufas NM, et al.. A randomized trial on the effect of phosphate reduction on vascular end points in CKD (IMPROVE-CKD). J Am Soc Nephrol. 2020, 31:2653-66. 10.1681\/ASN.2020040411","journal-title":"J Am Soc Nephrol"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1155\/2023\/9355672","article-title":"Effect of teriparatide on bone mineral density and bone markers in real-life: Argentine experience","volume":"2023","author":"Guelman R","year":"2023","unstructured":"Guelman R, S\u00e1nchez A, Varsavsky M, et al.. Effect of teriparatide on bone mineral density and bone markers in real-life: Argentine experience. Int J Endocrinol. 2023, 2023:9355672. 10.1155\/2023\/9355672","journal-title":"Int J Endocrinol"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfac043","article-title":"Effect of lanthanum carbonate on serum calciprotein particles in patients with stage 3-4 CKD-results from a placebo-controlled randomized trial","volume":"38","author":"Tiong MK","year":"2023","unstructured":"Tiong MK, Smith ER, Pascoe EM, et al.. Effect of lanthanum carbonate on serum calciprotein particles in patients with stage 3-4 CKD-results from a placebo-controlled randomized trial. Nephrol Dial Transplant. 2023, 38:344-51. 10.1093\/ndt\/gfac043","journal-title":"Nephrol Dial Transplant"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa031975","article-title":"The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis","volume":"349","author":"Black DM","year":"2003","unstructured":"Black DM, Greenspan SL, Ensrud KE, et al.. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med. 2003, 349:1207-15. 10.1056\/NEJMoa031975","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/303209-the-management-of-osteoporosis-in-chronic-kidney-disease-a-review-of-diagnostic-and-therapeutic-approaches","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T07:17:20Z","timestamp":1731914240000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/303209-the-management-of-osteoporosis-in-chronic-kidney-disease-a-review-of-diagnostic-and-therapeutic-approaches"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,17]]},"references-count":69,"URL":"https:\/\/doi.org\/10.7759\/cureus.73882","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,17]]}}}